CymaBay Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Newark CA United States (1988)

Organization Overview

First Clinical Trial
2006
NCT00353587
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

CymaBay Therapeutics, Inc. | Metabolex, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cholangitis (Phase 3)

Cholangitis, Sclerosing (Phase 2)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Fatty Liver (Phase 2)

Fibrosis (Phase 2)

Gout (Phase 2)

Hypercholesterolemia (Phase 2)

Hyperlipidemias (Phase 2)

Hyperlipoproteinemias (Phase 2)

Hyperlipoproteinemia Type II (Phase 2)

Hyperuricemia (Phase 2)

Liver Cirrhosis (Phase 2)

Liver Cirrhosis, Biliary (Phase 3)

Liver Diseases (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 23
  • # of Trial APIs: 11